October 22, 2015 News by Margarida Azevedo, MSc Biogen’s TYSABRI for Secondary Progressive MS Fails to Meet Phase 3 Trial Endpoints Biogen Inc. recently reported that the Phase 3 ASCEND clinical trial study testing TYSABRI efficacy in patients with secondary progressive multiple sclerosis (SPMS) did not achieve its primary and secondary goals. According to the company, the comprehensive results of the study will be revealed at a future medical conference.
September 9, 2015 News by Patricia Silva, PhD Smoking Can Accelerate Disease Progression in Patients with Multiple Sclerosis A new study entitled āEffect of Smoking Cessation on Multiple Sclerosis Prognosisā recently revealed that smoking by patients with multiple sclerosis (MS) postĀ diagnosis accelerates their disease progression course. The study was published in the journal JAMA Neurology and was led by researchers at the…
August 10, 2015 News by Patricia Inacio, PhD Apitope Completes Enrollment for Phase IIa Trial for Relapsing Multiple Sclerosis Apitope, a biocompany devoted to drug discovery and development for autoimmune diseases, announced that its partner Merck Serono has concluded the recruitment of participants forĀ its Phase IIa Trial on relapsing multiple sclerosis, (known as a Phase IIa study of ATX-MS-1467 or also M2736) The drug, ATX-MS-1467, is an…
June 15, 2015 News by Patricia Silva, PhD MediciNova Announces Update On Phase 2b Trial of MN-166 (Ibudilast) Involving 255 Progressive MS Patients MediciNova, Inc., a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the ongoing clinical trial of MN-166 (ibudilast) in patients with progressive multiple sclerosis (progressive MS) has finished the randomization of 255 patients, exceeding the…
March 11, 2015 News by Charles Moore SPMS Drug Developer Opexa Therapeutics To Receive $3M Payment from Merck Serono Under Amended Agreement Opexa Therapeutics, Inc. a biopharmaceutical company headquartered in Woodlands, Texas, has announced the successful conclusion of negotiations amending its option and license agreement with Darmstadt, Germany based pharma multinational Merck’s “Merck Serono” division. Under terms of the revised agreement, Opexa will receive a $3 million payment to…
February 13, 2015 News by Maureen Newman Experimental SPMS Drug From Innate Immunotherapeutics Shows Success in Early Trials Under development at Innate Immunotherapeutics is a special drug candidate to treat secondary progressive multiple sclerosis (SPMS). Currently, noĀ viable therapies exist for SPMS — only less-effective means to treat SPMS patients throughĀ drugs designed for relapse-remitting multiple sclerosis — making the prospect of Innate’s experimental SPMS therapy a…
January 19, 2015 News by Patricia Silva, PhD MedDay Provides Update on Pipeline Progress for Primary & Secondary Progressive Multiple Sclerosis Drug MedDay, a biotechnology company that develops new drugs for nervous system disorders, announced an update on the progress of its development pipeline with its leadĀ product MD1003 for the treatment of primary and secondary progressive multiple sclerosis (MS). The first study is expected to be complete in early 2015, while…
November 13, 2014 News by Charles Moore New Microparticle Secondary Progressive MS Therapy Dosing Tested In Australian Clinical Trial New Zealand and Australia-based Innate Immunotherapeutics Limited, a medical biotechnology company with offices in Sydney and Auckland, has issued an update regarding its Phase 2B trial for secondary progressive multiple sclerosis (SPMS) and other recent activities. The Phase 2B MIS416 trial Patient dosing with MIS416…
October 6, 2014 News by Charles Moore Australian Secondary Progressive MS Clinical Trial Tests New Microparticle Therapy New Zealand and Australia-based Innate Immunotherapeutics Limited, a biotechnology company with offices in Sydney and Auckland, has designed and manufactured a unique immunomodulator microparticle pharmaceutical technology. This technology can be used to induce the human immune system designed to fight certain cancers and infections, or modulate certain immune…
October 2, 2014 News by Patricia Inacio, PhD Multiple Sclerosis Patients Could Benefit From Placenta-based Cell Therapy Recent research reveals that placenta-based cell therapy is both safe and effective for treating both Relapsing-Remitting and progressive forms of MS. A new study entitled āHuman Placenta-Derived Cells (PDA-001) for the Treatment of Adults With Multiple Sclerosis: A Randomized, Placebo-Controlled, Multiple-Dose Studyā and published in August…
September 4, 2014 News by Patricia Silva, PhD Walking Speed in MS Patients May Indicate Worsening of Disease A dynamic research team composed of doctors and scientists recently completed and published a study that sought to gain a better understanding of walking impairment, as it is manifested in patients living with multiple sclerosis (MS), a neurodegenerative disease wherein the impulse-conducting myelin sheath is attacked by the body’s own…
September 1, 2014 News by Patricia Silva, PhD New Multiple Sclerosis Drug May Repair Nerve Demyelination As researchers continue to develop a clearer understanding of the underlying causes ofĀ multiple sclerosis (MS), it is becoming increasingly apparent that the future of treating the disease is likely to center on neural protection and a reversal of the demyelination process that strips away the critical insulation…
August 19, 2014 News by Patricia Silva, PhD 90 Secondary Progressive MS Patients To Be Recruited To Test Novel Experimental Therapy New Zealand and Ā Australian-based biotechnology company Innate ImmunotherapeuticsĀ recently announced that it has begun to recruit patients with Secondary Progressive Multiple Sclerosis (SPMS)Ā for its phase 2B trial of its experimental therapy MIS416. The study, which will be administered by theĀ Western Australian…
June 23, 2014 News by Patricia Silva, PhD Compassionate Use Trial of Innate Immunotherapeutics’ Multiple Sclerosis Drug Shows Positive Results Australian biotechnology companyĀ Innate Immunotherapeutics’ trial for a drug designed to treat secondary progressive multiple sclerosis (SPMS) has produced positive results. Innate’s experimental MIS416 has revealed benefits to the majority of SPMS patients who were prescribed it as a “compassionate use drug,” given the total lack of…
June 5, 2014 News by Maureen Newman Biogen Idec Investigates Tysabri in Secondary-Progressive Multiple Sclerosis Patients Biogen Idec is currently sponsoring a clinical trial evaluating its therapy Tysabri (natalizumab) in patients with secondary-progressive multiple sclerosis. Although relapse-remitting multiple sclerosis is more common and well-researched, the National Multiple Sclerosis Society estimates approximately half of relapse-remitting patients will transition to secondary-progressive within 19 years of diagnosis. The…